Abpro pens $4bn bispecific antibody deal with NJCTTQ

14:40 EST 1 Mar 2019 | Elsevier Business Intelligence

Abpro and Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ; a division of Chia Tai Tianqing Pharmaceutical Group Co....

Original Article: Abpro pens $4bn bispecific antibody deal with NJCTTQ

More From BioPortfolio on "Abpro pens $4bn bispecific antibody deal with NJCTTQ"